Kornimate/medical-research-clean huggingface dataset:
nyu/bellevue wtc health impacts research registry

Conditions: Exposure to World Trade Center Dust

Summary: the american red cross has funded a multidisciplinary, comprehensive evaluation and treatment program for target individuals with suspected world trade center (wtc)-related health problems. the populations served consist predominantly of a) local residents who were impacted by the disperion of the wtc dusts and fumes, b) individuals involved in cleaning and debris removal of local commercial spaces, and c) responders to the wtc collapse. these populations are recruited from past and ongoing programs that we have developed as well as from ongoing collaborations with community organizations that include: the beyond ground zero network, 9/11 environmental action committee, and the wtc residents coalition. in addition, there is collaboration with the charles b. wang community health center and the centers involved in the ongoing wtc workers and volunteer medical screening and monitoring program. we would now like to access the data from this treatment program to create a nyu/bellevue wtc health impacts research registry to increase knowledge about the health effects of exposure to world trade center dust.


Eligibility criteria:
target populations who will participate in the bellevue hospital red cross wtc health impacts program will include: * residents (children and adults) of lower manhattan communities at the time of the attacks, who remained or returned to their homes soon after the attacks * individuals involved in debris removal in surrounding commercial and residential buildings, * individuals involved in rescue, recovery and debris removal who have been previously screened through the world trade center worker and volunteer medical screening program and are in need of continued treatment.

Keywords: world trade center dust
development and validation of nomogram predicting survival in chinese sclc patients

Conditions: Small Cell Lung Cancer

Summary: in this retrospective study, patients diagnosed with sclc between january 2011 to september 2022 were identified from database of the second hospital of shandong university. following inclusion criteria should be met: (1) had histologically or cytologically confirmed newly diagnosed sclc; (2) no cancer treatment has been done before; (3) complete clinical, laboratory, imaging, treatment data and follow-up information. the exclusion criteria included: patients without complete records for pathological information, complete epidemiology and other key clinical information.

the investigators classified qualitative variables according to clinical practice. age included less than 60 years, 61-66 years, and more than 67 years. the primary tumor location included left-sided and right-sided. the anatomic sites included lower and others. the smoking status included never smoker and ever smoker. the forms of performance status according to the eastern cooperative oncology group scale (ecog ps) were ecog ≤ 2, and ecog ≥ 3. five groups were formed according to clinical t stage (t0-1, t2, t3, t4, and t stage that could not be evaluated). three groups were formed according to clinical n stage (n0-1, n2-3, and n stage that could not be evaluated). some stages were unevaluated, on account of a portion of non-measurable tumor size and lymph node. three groups were formed according to clinical m stage (m0, ma-b, mc). four groups were formed according to clinical tnm stage (ⅰ-ⅱ, ⅲ, ⅳ and tnm stage that could not be evaluated). the common metastatic sites(brain, liver, and bone) of tumor was divided into none and yes. the hematologic markers (serum natrium , lactate dehydrogenase, carcinoembryonic antigen, neuron-specific enolase, cytokeratin 19 fragment, and pro-gastrin-releasing peptide) were divided into normal and abnormal. the above information was collected before treatment. the recist version 1.0 was used to assess tumor responses after initial imaging studies of commencing chemotherapy. initial chemotherapy response is the first imaging examination of sclc patient after starting chemotherapy. six groups were formed according to initial response to chemotherapy (cr, pr, sd, pd, response that could not be evaluated, and no chemotherapy). other treatments (radiotherapy, surgery, targeted therapy, immunotherapy, interventional therapy, and whole-brain prophylactic cranial irradiation) was classified none and yes.

Eligibility criteria:
inclusion criteria: 1. newly diagnosis of small cell lung cancer 2. no cancer treatment has been done before 3. complete clinical, laboratory, imaging, treatment data and follow-up information exclusion criteria: 1. without complete records for pathological information, complete epidemiology and other key clinical information
longitudinal interaction between apoa5 -1131t>c and overweight accelerates arterial stiffness

Conditions: Overweight and Obesity

Summary: the aim of this study is to evaluate whether the longitudinal interaction between apoa5 -1131c variants and overweight could accelerate age-related increases in arterial stiffness and circulating triglycerides in healthy subjects.


Eligibility criteria:
inclusion criteria: * nondiabetic (fasting serum glucose concentration \< 126 mg/dl) * nonobese (bmi ≥ 25 kg/m2) exclusion criteria: * current and/or past history of cardiovascular disease * diabetes mellitus (fasting glucose levels ≥126 mg/dl) * abnormal liver or renal function * thyroid or pituitary disease * pregnancy or lactation * regular use of any medication
investigating the biomarkers in tumor and peripheral blood to evaluate the efficacy of cancer immunotherapy in chest cancer patients

Conditions: Lung Cancer; Esophageal Cancer

Summary: this study aims to investigate the impact of immunotherapy on the immune status of tumor microenvironment and peripheral blood of chest cancer patients. to do so, the investigators plan to collect tumor tissue and peripheral blood samples before and after immunotherapy, and use single-cell rna sequencing, multiplex immunohistochemistry, and flow cytometry. the investigators will analyze changes in the proportion of cancer cell-specific t-cell subpopulations related to treatment response before and after therapy, and seek biological markers that can predict the efficacy of immunotherapy.

the potential biomarkers, that can be utilized to predict the efficacy of cancer immunotherapy, in tumor tissue and peripheral blood are planning to be verified in lung cancer patients and esophageal cancer patients. tumor tissues, acquired from surgery to remove tumor, are investigated by single-cell rna sequencing, multiplex immunohistochemistry etc. to explore the biomarkers. in addition, immune microenvironment of the peripheral blood mononuclear cells were analyzed by flow cytometry and elispot to quantify specific t cells groups that are correlated with efficacy of cancer immunotherapy. the changes in the proportion of specific t-cell subpopulations that can kill cancer cells will be analyzed before treatment and after treatment. the immunotherapy responses before and after therapy are planning to analyzed with the content of specific t cells. thus the investigators will seek biological markers that can predict the efficacy of immunotherapy.

Eligibility criteria:
inclusion criteria: * patients with a pathological diagnosis of lung cancer or esophageal cancer who have agreed to receive pd-1/pd-l1 antibody immunotherapy; * age between 18 and 80 years old; * ecog ps score of 0 or 1; * adequate organ and bone marrow function; * anticipated survival time of at least 12 weeks; * willing and able to provide written informed consent. exclusion criteria: * patients with hematogenic infectious diseases, such as hiv, hepatitis b or hepatitis c. * patients with tumor emergencies that require immediate treatment. * poor vascular conditions. * abnormal coagulation function or receiving anticoagulant or thrombolytic therapy. * patients with hematogenic infectious diseases, such as hbv. * patients with psychiatric disorders or severe mental illnesses. * patients who have difficulty communicating or are unable to be followed up for a long time. * other situations that are not suitable for inclusion in the study.

Keywords: cancer immunotherapy peripheral blood pbmc t cells tumor antigen specific t cells
a retrospective study evaluating the efficacy and safety of micafungin sodium in the treatment of invasive fungal infections

Conditions: Invasive Fungal Infections

Summary: the objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients with invasive fungal infections caused by candida sp. or aspergillus sp. (fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in china.


Eligibility criteria:
inclusion criteria: * patients who received micafungin as empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy * patients received micafungin treatment at least 1 dose exclusion criteria: * patients received micafungin treatment combined with other antifungal drugs at the same time * neither efficacy or safety can be evaluated because of missing data, confused record

Keywords: micafungin candida aspergillosis antifungal
evaluating the effects of adjunctive aripiprazole on weight and metabolic outcomes in females

Conditions: Psychosis; Metabolic Syndrome; Weight Gain

Summary: patients with psychiatric disorders, including depression, anxiety, and schizophrenia, often require antipsychotic medications for symptom management. however, metabolic changes, especially weight gain, are a common and challenging side effect of many antipsychotics. aripiprazole, an atypical antipsychotic, has shown promise in mitigating this adverse effect when used in combination with other antipsychotic medications.

this study aims to investigate the effectiveness of different combinations of aripiprazole with atypical antipsychotics in preventing or minimizing weight gain in patients with various psychiatric conditions. while weight gain affects both genders, females may be particularly vulnerable due to physiological differences and societal pressures related to body image. collectively, while individual studies have specific nuances, the general trend suggests that combining aripiprazole with dietary modifications and potentially lifestyle changes shows promise in managing weight gain associated with antipsychotic medications in females.

Eligibility criteria:
inclusion criteria: * females aged 18-65 years diagnosed with a mental health condition necessitating antipsychotic treatment. * diagnosis of schizophrenia or schizoaffective disorder * on stable doses of atypical antipsychotics, either olanzapine, clozapine, or risperidone for at least 1 month * willingness to comply with the study protocol. exclusion criteria: * pregnancy or lactation. * severe medical conditions impacting weight or metabolism. * previous intolerance or contraindications to aripiprazole. * non-compliant with prescribed medications * mental retardation * participant with an eating disorder * participants with serious suicidal thoughts, or who pose a serious risk of harm to self or to others. * diagnosis of hyper or hypothyroidism; evidence of thyroid dysfunction as evidenced by serum thyroid function tests (i.e thyroid stimulating hormone and -free thyroxine (ft4) levels \&gt; 10 % above or below the limits of the normal range use of any medication for weight loss within the past one month to the study entry * clinically significant abnormalities in physical examinations, ecg or lab assessments
quality of life after open heart surgery in older patients

Conditions: Open Heart Surgery Patients

Summary: long term follow-up of nonagenarians who have undergone open heart procedures.

based on population studies, life expectancy at age 80 is 8.5 years, and at the age of 85 years, it is 6.3 years (us bureau of census 2000). there are currently 1.6 million nonagenarians and roughly 72,000 centenarians living in the united states. with this increasing elderly population, knowledge of the special management issues and long-term sequela are imperative. bacchetta and coworkers from our institution presented a 10-year outcomes experience in nonagenarians undergoing cardiac surgery. in 42 consecutive patients, in-hospital mortality was 7%, and 30-day mortality 5%. postoperative morbidity was documented in 67% with arrhythmias accounting for 31% of the cases, followed by respiratory complications, infections, and strokes. while this is mostly in-hospital data, long-term follow-ups have not been performed.

Eligibility criteria:
inclusion criteria: * patients who underwent open heart procedures and who were 90 years or greater between 1995 and 2004 at the new york presbyterian hospital exclusion criteria: * patients who refuse follow-up

Keywords: nonagenarians quality of life cardiothoracic surgery long term survival
is acupuncture able to reduce nausea and vomiting in the terminal ill patient

Conditions: Terminal Illness

Summary: a comparative effectiveness research design was used. the sample size was calculated to 136 patients, who were randomized to an intervention group and a control group respectively. the patients were terminal ill patients enrolled to three in-bed hospices in denmark and nausea and vomiting were measured using eortc qlq-c15-pal (european organisation for research and treatment of cancer, quality of life questionaire, core 15, palliation)

the terminal ill patient is suffering from many different symptoms. in total 70% are suffering from nausea and vomiting due to the wide spread of cancer or due to side effects of treatment. often the antiemetic's are not able to reduce symptoms to a level that enable the patient to experience quality in life in the last days of his life. the investigators had some experience with acupuncture as a complementary therapy but the investigators wanted more systematically to investigate if acupuncture is able to reduce the terminal ill patient´s nausea and vomiting. literature show that acupuncture is able to reduce nausea and vomiting in patients receiving chemotherapy, but there is no literature that support the ability of acupuncture to reduce nausea and vomiting in the terminal ill patient. the purpose of this study was to generate evidence based knowledge close to practice regarding the effect of acupuncture in reducing nausea and vomiting in the terminal ill patient. participants: terminal ill patients suffering from nausea and/or vomiting interventions: the intervention group received usual care plus acupuncture for three days. the acupuncture spots: pericardium-6, stomach-36, liver-3 and yin tang were used. the control group received usual care.

Eligibility criteria:
inclusion criteria: * able to participate due to cognitive ability * nausea * admitted to in-bed hospice exclusion criteria: * not able to participate due to cognitive impairment * lymphedema in the area of acupuncture site

Keywords: acupuncture nausea vomiting palliative care
ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome and a high bleeding risk: optimization of antiplatelet treatment in high-risk elderly

Conditions: Non-ST-elevation Acute Coronary Syndrome; Unstable Angina; Non-ST-elevation Myocardial Infarction

Summary: a randomized controlled, open label, multicenter trial with 1000 patients aged 70 years and older, presenting with non-st-elevation acute coronary syndrome. patients will be randomized to either clopidogrel or the novel p2y12 inhibitor (ticagrelor or prasugrel). patients will be followed for one year for outcomes such as bleeding episode requiring medical intervention and net clinical benefit (all cause mortality, non-fatal myocardial infarction, non-fatal stroke, plato major and minor bleeding).


Eligibility criteria:
inclusion criteria: * at least 70 years of age. * hospitalization for nstemi or ua \< 72 hours exclusion criteria: * contraindication to p2y12 inhibitors i.e. clopidogrel, prasugrel or ticagrelor: * unable or unwilling to give informed consent or have a life expectancy of less than one year. * having received thrombolytic therapy within the previous 24 hours. * severe renal function impairment needing dialysis. * confirmed or persistent severe hypertension (systolic blood pressure (sbp) \> 180 mmhg and/or diastolic blood pressure (dbp) \>110 mmhg) at randomization. * at increased bleeding risk, at the investigator's opinion, e.g. because of malignancy. * cardiogenic shock (sbp ≤ 80mmhg for \>30 mins) or intra-aortic balloon pump (iabp) at the time of screening. * history of major surgery, severe trauma, fracture or organ biopsy within 90 days prior to randomisation. * clinically significant out of range values for platelet count or haemoglobin at screening, in the investigator's opinion. * acs under dual antiplatelet therapy, e.g. aspirin with a p2y12 inhibitor; clopidogrel, prasugrel, ticagrelor. * patients with a known cyp2c19 genotype at the time of randomization.

Keywords: elderly p2y12 inhibitors clopidogrel ticagrelor
a research study of how faster-acting insulin aspart moves into, through, and out of the body and how it works in the body when given through an insulin pump to people with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: the aim of the study is to compare the pharmacokinetics (i.e. the course of the blood concentrations of the administered trial drug) of faster-acting insulin aspart (faster aspart), and the currently marketed formulation of insulin aspart (novorapid®) when given as a bolus using an insulin pump in people with type 1 diabetes. the pharmacodynamic response (i.e. the course of the blood sugar lowering effect of the administered trial drug) and the safety and tolerability of faster aspart and novorapid® will also be assessed. the participants will be in the study for approx. 21 days. each participant will have 5 visits to the clinic, with an overnight stay at both dosing visits. participants will have a number of tests, and they will have to give blood and urine samples.


Eligibility criteria:
inclusion criteria: * male or female aged 18 - 64 years (both inclusive) at the time of signing informed consent. * type 1 diabetes mellitus (as diagnosed clinically) for 12 months or longer. * body mass index 18.5 - 28.0 kg/sqm (both inclusive). * treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (csii) for 12 months or longer. exclusion criteria: * subject who has donated any blood or plasma in the past month or more than 500 ml within 3 months prior to screening. * smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily). * not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period.
a study to evaluate the effect of iv doses of rivipansel on subjects with renal impairment and in healthy subjects

Conditions: Renal Impairment; Healthy

Summary: the purpose of this study is to determine the effect of renal impairment on rivipansel.


Eligibility criteria:
inclusion criteria: * female subjects of non-childbearing potential or male subjects * body mass index (bmi) of 17.5 to 40.0 kg/m2 * stable renal function exclusion criteria: * a positive urine drug screen for illicit drugs * treatment with an investigational drug within 30 days of the dose of study medication * pregnant females, breastfeeding female subjects and male subjects with partners currently pregnant * use of herbal supplements in the 28 days prior to the dose of study medication * blood donation (excluding plasma donation) of approximately 1 pint or more within 56 days prior to study medication * requiring dialysis

Keywords: renal insufficiency
triple combination therapy of choroidal neovascularization in amd, a cost effect and efficient therapeutic treatment

Conditions: Exudative Macular Degeneration

Summary: we propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (bevacizumab, dexamethasone and photo-dynamic therapy) during the years of 2006 to 2010 at the retina center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin.

study parameters will include best corrected visual acuity, number of combination treatments, reduction of central foveal thickness by oct measurement and development of exudative macular degeneration in the fellow eye. follow up will include all patients with a minimum of two years. retrospective review of patient charts in the office of the retina center.

Eligibility criteria:
inclusion criteria: - must have age related macular degeneration exclusion criteria: -
abu dhabi diabetes and obesity study -2 bariatric

Conditions: Bariatric Surgery Candidate

Summary: study on outcomes on bariatric surgery, particularly in terms of metabolic parameters in the uae is scant. also genetic data from this population is limited and hence a study on genetic determinants of response to bariatric surgery is highly warranted. this study is expected to provide a better understanding of the causes of severe obesity in the uae population and help us to evaluate the efficacy of bariatric surgery in patients with genetic forms of obesity. the information generated will allow us to better advise patients regarding the risks and benefits of bariatric surgery as a treatment. objective to investigate the metabolic outcomes of bariatric surgery, to study the prevalence of monogenic forms of obesity among a cohort of patients with morbid obesity who underwent bariatric surgery and to compare the outcomes of bariatric surgery in patients with and without underlying genetic condition.

prior to participation, the nature of the study, the objectives of the study, the study procedures and any known or likely risks including specific information pertaining to the genetic testing technology will be explained to the subjects by the study team. written informed consent will be obtained after providing an information sheet with details regarding the study including the genetic analysis performed. the information sheet with consent form will be available in arabic and english. the participant (or parent/guardian or legally authorised representative, as appropriate) must personally sign and date the latest approved version of the icf before any study specific procedures are performed. a copy of the signed icf will be kept in the medical record, with the study data, and provided to the participant. the original signed icf will be retained at the study site for 10 years after the end of the project and should be conveyed to icldc, to be stored electronically, for its records. each subject will be informed that their source medical records may be checked by representatives from the responsible authorities (icldc rec, adhrtc, doh) with applicable regulations. however, they will be made aware that all information will be treated with confidentiality.

Eligibility criteria:
inclusion criteria: * patients attending icldc who are planning to undergo, or who have already undergone bs for treatment of severe obesity. exclusion criteria: * any malignant or chronic inflammatory disease, * children in the absence of parental consent * anyone who is not able to take part for reasons of significant incapacity or disability, including mental disability, preventing discussion of clinical history.

Keywords: bariatric surgery resting metabolic rate monogenic obesity
single embryo transfer versus double embryo transfer

Conditions: Infertility

Summary: the aim of this project is to study the best number (1 or 2)and day (3 vs 5)of embryo transfer in good prognosis patient.


Eligibility criteria:
inclusion criteria:g * good prognosis ivf patients exclusion criteria: * bad prognosis ivf patients

Keywords: infertility ivf set det blastocyst